We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

This study is currently recruiting participants.
Verified March 2017 by Intra-Cellular Therapies, Inc.
ClinicalTrials.gov Identifier:
First Posted: June 29, 2016
Last Update Posted: August 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Intra-Cellular Therapies, Inc.
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.

Condition Intervention Phase
Agitation in Dementia, Including Alzheimer's Disease Drug: ITI-007 Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Intra-Cellular Therapies, Inc.:

Primary Outcome Measures:
  • Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C) [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Clinical Global Impression Scale for Severity of Illness (CGI-S) [ Time Frame: 4 weeks ]

Estimated Enrollment: 360
Actual Study Start Date: June 2016
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ITI-007
9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks
Drug: ITI-007
Placebo Comparator: Placebo
Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
Drug: Placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of probable Alzheimer's disease
  • Clinically significant symptoms of agitation secondary to probable Alzheimer's disease
  • Able to attend outpatient clinic visits with primary caregiver

Exclusion Criteria:

  • Unable to comply with study procedures
  • Considered medically inappropriate for study participation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02817906

Contact: Kimberly Vanover, Ph.D. itciclinicaltrials@intracellulartherapies.com

United States, Arizona
Sun City, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
Rogers, Arkansas, United States
United States, California
Costa Mesa, California, United States
Glendale, California, United States
Irvine, California, United States
Lemon Grove, California, United States
Long Beach, California, United States
Oceanside, California, United States
Riverside, California, United States
San Diego, California, United States
Santa Ana, California, United States
United States, Florida
Hallandale Beach, Florida, United States
Hialeah, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
United States, Georgia
Suwanee, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Berlin, New Jersey, United States
Marlton, New Jersey, United States
Toms River, New Jersey, United States
United States, New York
Brooklyn, New York, United States
Staten Island, New York, United States
United States, Ohio
Centerville, Ohio, United States
Dayton, Ohio, United States
United States, Texas
San Antonio, Texas, United States
Sponsors and Collaborators
Intra-Cellular Therapies, Inc.
Study Director: Kimberly Vanover, Ph.D. Intra-Cellular Therapies, Inc.
  More Information

Responsible Party: Intra-Cellular Therapies, Inc.
ClinicalTrials.gov Identifier: NCT02817906     History of Changes
Other Study ID Numbers: ITI-007-201
First Submitted: June 27, 2016
First Posted: June 29, 2016
Last Update Posted: August 16, 2017
Last Verified: March 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Alzheimer Disease
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms